TY - JOUR
T1 - Sequential intra-arterial infusion of 90Y-resin microspheres and mitomycin C in chemo refractory liver metastatic breast cancer patients: a single centre pilot study
AU - Aarts, Brigitte Maximiliana
AU - Klompenhouwer, Elisabeth Genevieve
AU - Dresen, Raphaela Carmen
AU - Deroose, Christophe Michel Albert Louis Omer
AU - Beets-Tan, Regina Gien Hoa
AU - Punie, Kevin
AU - Neven, Patrick
AU - Wildiers, Hans
AU - Maleux, Geert
N1 - Publisher Copyright:
© 2020 2020 Brigitte Maximiliana Aarts, Elisabeth Geneviève Klompenhouwer, Raphaëla Carmen Dresen, Christophe Michel Albert Louis Omer Deroose, Regina Gien Hoa Beets-Tan, Kevin Punie, Patrick Neven, Hans Wildiers, Geert Maleux, published by Sciendo.
PY - 2020/3
Y1 - 2020/3
N2 - Background. The aim of the study was to evaluate the safety and feasibility of intra-arterial mitomycin C (MMC) infusion after selective internal radiation therapy (SIRT) using Yttrium-90 (Y-90) resin microspheres in liver metastatic breast cancer (LMBC) patients.Patients and methods. The prospective pilot study included LMBC patients from 2012-2018.Patients first received infusion of Y-90 resin microspheres, after 6-8 weeks response to treatment was assessed by MRI, F-18-FDG PET/CT and laboratory tests. After exclusion of progressive disease, MMC infusion was administrated 8 weeks later in different dose cohorts; A: 6 mg in 1 cycle, B: 12 mg in 2 cycles, C: 24 mg in 2 cycles and D: maximum of 72 mg in 6 cycles. In cohort D the response was evaluated after every 2 cycles and continued after exclusion of progressive disease. Adverse events (AE) were reported according to CTCAE version 5.0.Results. Sixteen patients received Y-90 treatment. Four patients were excluded for MMC infusion, because of extra hepatic disease progression (n = 3) and clinical and biochemical instability (n = 1). That resulted in the following number of patient per cohort; A: 2, B: 1, C: 3 and D: 6. In 4 of the 12 patients (all cohort D) the maximum dose of MMC was adjusted due biochemical toxicities (n = 2) and progressive disease (n = 2). One grade 3 AE occurred after Y-90 treatment consisting of a gastrointestinal ulcer whereby prolonged hospitalization was needed.Conclusions. Sequential treatment of infra-arterial infusion of MMC after Y-90 SIRT was feasible in 75% of the patients when MMC was administrated in different escalating dose cohorts. However, caution is needed to prevent reflux after Y-90 SIRT in LMBC patients.
AB - Background. The aim of the study was to evaluate the safety and feasibility of intra-arterial mitomycin C (MMC) infusion after selective internal radiation therapy (SIRT) using Yttrium-90 (Y-90) resin microspheres in liver metastatic breast cancer (LMBC) patients.Patients and methods. The prospective pilot study included LMBC patients from 2012-2018.Patients first received infusion of Y-90 resin microspheres, after 6-8 weeks response to treatment was assessed by MRI, F-18-FDG PET/CT and laboratory tests. After exclusion of progressive disease, MMC infusion was administrated 8 weeks later in different dose cohorts; A: 6 mg in 1 cycle, B: 12 mg in 2 cycles, C: 24 mg in 2 cycles and D: maximum of 72 mg in 6 cycles. In cohort D the response was evaluated after every 2 cycles and continued after exclusion of progressive disease. Adverse events (AE) were reported according to CTCAE version 5.0.Results. Sixteen patients received Y-90 treatment. Four patients were excluded for MMC infusion, because of extra hepatic disease progression (n = 3) and clinical and biochemical instability (n = 1). That resulted in the following number of patient per cohort; A: 2, B: 1, C: 3 and D: 6. In 4 of the 12 patients (all cohort D) the maximum dose of MMC was adjusted due biochemical toxicities (n = 2) and progressive disease (n = 2). One grade 3 AE occurred after Y-90 treatment consisting of a gastrointestinal ulcer whereby prolonged hospitalization was needed.Conclusions. Sequential treatment of infra-arterial infusion of MMC after Y-90 SIRT was feasible in 75% of the patients when MMC was administrated in different escalating dose cohorts. However, caution is needed to prevent reflux after Y-90 SIRT in LMBC patients.
KW - liver metastatic breast cancer
KW - chemo resistant
KW - infra-arterial therapy
KW - radioembolization
KW - selective internal radiation therapy
KW - mitomycin C infusion
KW - Y-90 RADIOEMBOLIZATION
KW - HEPATIC METASTASES
KW - PROGNOSTIC-FACTORS
KW - CENTER EXPERIENCE
U2 - 10.2478/raon-2020-0002
DO - 10.2478/raon-2020-0002
M3 - Article
C2 - 31967966
SN - 1318-2099
VL - 54
SP - 33
EP - 39
JO - Radiology and Oncology
JF - Radiology and Oncology
IS - 1
ER -